Phase II Study of TRC102 in Combination With Temozolomide for Recurrent Glioblastoma

Trial Profile

Phase II Study of TRC102 in Combination With Temozolomide for Recurrent Glioblastoma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Dec 2017

At a glance

  • Drugs Temozolomide (Primary) ; TRC 102 (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Nov 2017 According to a TRACON Pharmaceuticals media release, data expepected in 2018.
    • 17 Aug 2017 Planned primary completion date changed from 31 Aug 2017 to 31 Mar 2018.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top